Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy

Date

21 Oct 2023

Session

Poster session 09

Topics

Basic Science

Tumour Site

Cervical Cancer

Presenters

Stéphanie Calfa

Citation

Annals of Oncology (2023) 34 (suppl_2): S187-S214. 10.1016/S0923-7534(23)01931-2

Authors

S. Calfa1, A.J.A. de Freitas2, T.T. Komoto1, C.R. Nunes3, J.C..P. Resende4, R. dos Reis5, R.M. Reis2, M.M.C. Marques2

Author affiliations

  • 1 Molecular Oncology Research Center, Hospital de Amor (Hospital De Cancer De Barretos) - Fundacao Pio XII, 14784-400 - Barretos/BR
  • 2 Molecular Oncology Research Center, Barretos Cancer Hospital, 14.784-400 - Barretos/BR
  • 3 Centro De Oncologia Molecular, Barretos Cancer Hospital, 14.784-400 - Barretos/BR
  • 4 Department Of Prevention, Hospital de Amor (Hospital De Cancer De Barretos) - Fundacao Pio XII, 14784-400 - Barretos/BR
  • 5 Department Of Gynecological Oncology, MD Anderson Cancer Center, 77030 - Houston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 31P

Background

Cervical cancer (CC) is the fourth most common type of cancer among women worldwide. Considering that the early diagnosis of cervical intraepithelial neoplasia (CIN) is the main strategy to improve the prognosis of patients, new methodologies based on molecular analyzes performed on liquid biopsy samples, represent promising alternatives for minimally invasive biomarkers. miRNAs have been shown their role as non-invasive biomarkers, providing a wide perspective for personalized treatment and early diagnosis of cervical cancer through liquid-based cytology (LBC). However, more research is under way to identify miRNA signatures that can be implemented in clinical practice specially for early detection. In this study, we aimed to identify molecular signatures of miRNAs in cervical precursor lesions (CIN 2 and CIN 3) from LBC and their interaction with molecular pathways related to CC in a prospective study.

Methods

We analyzed 96 LBC cervical samples, that were divided into two groups: the case group was composed of women diagnosed with CIN 2 and CIN3 (n = 48); the control group corresponded to women without cervical precursor lesions (n = 48). We performed miRNA expression profiling using the nCounter® miRNA Expression Assay (NanoString Technology), which evaluated 800 targets. A functional analysis in silico was performed by mirDIP and enrichment were performed using Cytoscape with the Reactome plugin.

Results

We identified 54 miRNAs that were differentially expressed between case and control groups (p ≤ 0.05). Using logistic regression analysis, we identified a signature composed of five miRNAs, with a fold change ≥ 1.5 and FDR-corrected p-value of ≤ 0.05, of which two were up-regulated and three were down-regulated. The signature had a predictive value with an AUC of 0.90. Furthermore, we found 26 miRNA target genes for four of the five identified miRNAs, mainly related to pathways in cancer, RNA Polymerase II Transcription, RhoA signaling pathway, and PI3K-Akt signaling pathway.

Conclusions

This study demonstrated that those miRNAs could be used as non-invasive biomarkers in LBC samples, once they were able to distinguish CIN 2 and CIN3 patients from healthy women and regulate important molecular pathways of onset carcinogenesis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Barretos Cancer Hospital.

Funding

Programa Nacional de Apoio à Atenção Oncológica.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.